Acquisitions:

1. Zydus Life acquires US-based Assertio for US$166 Million cash.
2. Gujarat Themis Biosyn acquires MicroBiopharm Japan for INR 1,300 Cr (US$136 Million).
3. Anupam Rasayan to acquire 43.3%–48.2% equity stake in Bliss GVS Pharma.
4. IKS Health to acquire TruBridge in $26.25-a-share deal to expand rural healthcare reach.
5. True North partners with Embio to support API-manufacturing capabilities.
6. Piramal Pharma Solutions inks partnership with Botanix to support drug substance development.
7. Angelini Pharma is spending US$4.1 Billion to buy Catalyst Pharmaceuticals and its trio of FDA-approved treatments for rare neurological diseases.
8. Bayer to acquire biopharma company Perfuse Therapeutics in up to US$2.45 Billion deal.
9. OrganaBio acquires Excellos assets, expanding US operations.

Licensing:

1. Shilpa Medicare signs long-term CDMO pact with NXI Therapeutics to expand global biotech push.
2. Neuland Labs and LIR Life partner on next-gen transdermal GLP-1 obesity therapy platform.
3. Medtronic inks US$650 Million deal for SPR Therapeutics.
4. Olympus pushes deeper into oncology with US$270 Million BioProtect deal.
5. Incyte pays Genesis US$80 Million to expand AI-fueled drug discovery pact.

Investments/Fund Raising:

1. Altimmune secures US$225 Million financing for pemvidutide development.
2. CellCentric raises US$220 Million to get multiple myeloma pill to market.
3. Cartesian Therapeutics secures up to US$150 Million financing.
4. Signos raises US$20 Million as it eyes health plan, pharma relationships.
5. Kotak Alts invests INR 20 Cr (US$2.1 Million) in Cellogen Therapeutics.

1. New Client Win: Innovative Autoinjector company from Europe.
2. New Project from Existing Client: Aagami has received new assignment from Chicago based client for their Strategic Partnering/Investment for their Phase 3 stage patented asset for Resuscitation from Sudden Cardiac Arrest.
3. New Project from Past Client: French client with late stage smoking cessation injectable asset has appointed Aagami for a new partnering assignment.
4. BIO Internation Convention (Jun 22-25 - San Diego): Our calendar is filling up fast for meetings . Please send us your meeting requests soon.

For Partnering/Licensing/ Co-development:

1. Seeking Licensing / Distribution Partners: Marketed Povidone-Iodine Nasal Spray (Nasodine®), patented, clinically proven to eliminate respiratory viruses and bacteria, offering safe and effective relief from cold, flu, and nasal congestion. Commercially launched in Singapore (2024) as an antiseptic liquid, with all government hospitals adoption and strong retail traction; Offering an attractive ready-to-launch Consumer wellness OTC opportunity in multiple markets (except Singapore, Brunei, Malaysia and the Philippines where already partnered).
2. Seeking Co-development Partner/Investor for Phase 3 stage Erythropoietin (EPO) patented asset for Resuscitation from Sudden Cardiac Arrest (A groundbreaking approach). By using the 351(A) dossier, an easy and quick path via 351 (K) Biosimilar approval for multiple indications may also be obtained.
3. Seeking Co-development/Out-Licensing: Phase 3 stage small molecule first-in-class eye drop to treat pre-surgical cataract (typically for patients 40 to 72 years of age).
4. Seeking Partnering/Co-development : Uncoupling Metastasis and Proliferation with translational platform, using Machine Learning and known molecules to disrupt cancer treatment. Lead asset (Phase 2) and platform, both available for licensing.
5. Seeking Licensing/Partnering: Phase 2 Drug poised to revolutionize antiviral treatment; could be a single drug to treat all the "tripledemic" viruses (RSV, FLU, COVID). Also, Phase 2 trials are starting in Central Africa for MPOX. Very effective in Bird Flu and Measles too.
6. Dental gel (Marketed in the US & approved in EU) for Prevention & Treatment of Periodontitis, Gingivitis, & Caries. Featured in WSJ, FOX, NBC, ABC, GQ. Already a profit-making product. Licensing available.
7. Seeking Licensing / Co-development / Platform Partnering: FDA-validated Ionic Liquid (IL) enabled drug delivery platform addressing solubility, permeability, and bioavailability challenges. Enables non-invasive systemic delivery via transdermal and oral routes, including peptides and nucleic acids. Clinically validated with an FDA-approved IL-enabled product and demonstrated ~6× improvement in oral bioavailability (e.g., Semaglutide). Platform licensing, molecule-specific licensing, and joint R&D collaborations available. Email us about your challenging molecules at action@aagami.com.
8. Available for Licensing/Co-development: Biosimilars such as Adalimumab, Rituximab, & Infliximab with ~2028 market launch timeline.

For Acquisition:

1. [URGENT] Lucrative (Less than $500K) Opportunity to acquire IP Portfolio (bankruptcy disposition) of clinical stage First-in-Class Non-Opioid Analgesic. Few discussions already ongoing. 2 Bids under evaluation.
2. Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology for Next-generation biologics, its product candidates, data package of ~20 drug candidates, IP, NOL and Federal benefits etc.
3. A High Multiple ROI by acquiring small molecule clinical asset in rare diseases (sickle cell disease & thalassemia). (Two Phase 1 completed. Phase 2 ready). Low cost and quicker to market vs. Gene Therapy. Their previous asset was acquired for US$400 million.

For Investment:

1. Partnering/Investment open for optimized technology from AU to farm Beta carotene and other valuable nutraceuticals from Algae.
   1. The enhanced version of a globally proven Tech brings significant cost efficiency and productivity.
   2. An Investment/partnering deal will finalize first commercial-scale facility, optimize corporate governance, and prepare for global expansion, offering strategic partners a low-risk entry into a high-demand, clean-label supply chain.
2. High ROI Opportunity to Invest (Series C) in U.S.based medtech revolutionizing medical imaging with the world’s first portable, single-sided MRI platform (On the market for 4 years). Exit via an IPO, strategic M&A, or private equity buyout.
3. Seeking Investment (~INR 20 Crore Commitment received): Join Investors such as BIRAC in uncoupling Metastasis and Proliferation with translational platform, using Machine Learning and known molecules to disrupt cancer treatment. The funds will be used to progress the pipeline to the out-licensing stage.
4. Seeking Investment: Revolutionizing oncology with patented smart drug delivery platform that enhances chemotherapy efficacy while minimizing toxic side effects. Backed by US$14 million in funding and a team with 7 prior drug launches, client is advancing a pipeline of 5 chemotherapies toward IND. Targeting US$180 billion+ oncology market.

Hope you found the content useful. We welcome your feedback and queries.